Generic Exclusivity Forfeiture Provision Hits Snag In Courts; FTC Wants Fix

A key provision of the Medicare Modernization Act's forfeiture provision for ANDA filers' 180-day exclusivity could be moot if courts continue to refuse to hear petitions by generic companies for declaratory judgments

More from Archive

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.